|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
RET/PTC Rearrangement, Thyroid Cancer
Test Code90473
CPT Codes
81404
Includes
RET/PTC1, RET/PTC3
Preferred Specimen
1 formalin-fixed, paraffin-embedded tissue block
Other Acceptable Specimens
Needle washing (see instructions)
Instructions
Do not reject.
Needle washings in alcohol-based fixative (e.g. CytoLyt®) or formalin-fixed, paraffin-embedded tissue block FNA or FFPE specimens are acceptable for the assay.
All specimens must be accompanied with Pathology report. All FFPE specimens will be examined by a pathologist for confirmation and adequacy. Macrodissection if warranted is performed in the lab.
Needle washings in alcohol-based fixative (e.g. CytoLyt®) or formalin-fixed, paraffin-embedded tissue block FNA or FFPE specimens are acceptable for the assay.
All specimens must be accompanied with Pathology report. All FFPE specimens will be examined by a pathologist for confirmation and adequacy. Macrodissection if warranted is performed in the lab.
Transport Temperature
Room temperature
Specimen Stability
FNA or FFPE
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable
Needle washings
Room temperature: 30 days
Refrigerated: 30 days
Frozen: Unacceptable
Room temperature: 5 years
Refrigerated: 5 years
Frozen: Unacceptable
Needle washings
Room temperature: 30 days
Refrigerated: 30 days
Frozen: Unacceptable
Methodology
Real-Time Polymerase Chain Reaction (PCR)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Daily; Report available: 5 days
Reference Range
| RET/PTC1 | Not detected |
| RET/PTC3 | Not detected |
Clinical Significance
RET/PTC gene fusion is detected in 5-40% of papillary thyroid carcinomas, but has been reported at low frequency in other types of thyroid lesions. Correlation with morphologic and clinical findings is thus required.
The assay tests for both RET/PTC1 and RET/PTC3 rearrangements using a reverse transcription PCR assay. The lower limit of sensitivity is approximately 2.5% mutation-bearing cells in a mixed sample, but can vary due to RNA preservation.
The assay tests for both RET/PTC1 and RET/PTC3 rearrangements using a reverse transcription PCR assay. The lower limit of sensitivity is approximately 2.5% mutation-bearing cells in a mixed sample, but can vary due to RNA preservation.
Performing Laboratory
| Quest Diagnostics Nichols Institute |
| 14225 Newbrook Drive |
| Chantilly, VA 20153 |
